Salud financiera de hoja de balance de Core Laboratories
Salud financiera controles de criterios 6/6
Core Laboratories tiene un patrimonio de accionistas total de $275.1M y una deuda total de $114.5M, lo que sitúa su ratio deuda-patrimonio en 41.6%. Sus activos y pasivos totales son $587.7M y $312.6M respectivamente. El BAIT de Core Laboratories es de $49.2M, por lo que su ratio de cobertura de intereses es de 4.5. Tiene efectivo e inversiones a corto plazo que ascienden a $22.8M.
Información clave
41.60%
Ratio deuda-patrimonio
US$114.46m
Deuda
| Ratio de cobertura de intereses | 4.5x |
| Efectivo | US$22.82m |
| Patrimonio | US$275.14m |
| Total pasivo | US$312.58m |
| Activos totales | US$587.73m |
Actualizaciones recientes sobre salud financiera
We Think Core Laboratories (NYSE:CLB) Is Taking Some Risk With Its Debt
Jul 24
Is Core Laboratories (NYSE:CLB) Using Too Much Debt?
Nov 12We Think Core Laboratories (NYSE:CLB) Can Stay On Top Of Its Debt
Jul 15Recent updates
CLB: Fair Outlook Balances Middle East Disruptions And Governance Changes
Analysts have raised their price target on Core Laboratories from about $14.00 to roughly $16.33, citing updated views on fair value, discount rate, revenue growth, profit margins, and future P/E assumptions. What's in the News Core Laboratories revised its first quarter 2026 earnings guidance, citing client driven project delays, travel constraints, and supply chain disruptions linked to geopolitical conflict in the Middle East, and now expects revenue of US$119,000,000 to US$123,000,000 and EPS, ex items, of US$0.05 to US$0.07 for the period (Key Developments).
CLB: Fair Value View Will Rely On Middle East Risk And P/E Assumptions
Analysts have raised their price target on Core Laboratories from $18 to $22, citing updated assumptions around revenue growth, profit margins, and a slightly higher future P/E multiple as key drivers of the change. What's in the News Core Laboratories revised its first quarter 2026 earnings guidance, citing client driven project delays, travel constraints, and supply chain disruptions linked to geopolitical conflict in the Middle East, and now expects revenue of US$119,000,000 to US$123,000,000, operating income ex items of US$5,700,000 to US$7,100,000, and Earnings Per Share ex items of US$0.05 to US$0.07 (Key Developments).Core Laboratories: Profit Margins Are Too Small To Get Excited About
Mar 26CLB: Fair Value View Will Rely On Stable Margins And P/E Assumptions
Analysts held their price target on Core Laboratories steady at US$18.00, citing only small tweaks to inputs such as discount rate, revenue growth, profit margin and future P/E assumptions, rather than any major shift in their overall view of the company. Valuation Changes Fair Value: Held steady at US$18.00, indicating no change in the core valuation output.CLB: Fair Value View Will Rely On Stabilizing Margins And EPS
Analysts kept their Core Laboratories fair value estimate around $18.00. The updated price target mainly reflects slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E rather than a major shift in their view of the stock.CLB: Future Earnings And Margins Are Expected To Gradually Stabilize
Analysts have modestly reduced their price target on Core Laboratories by 1 dollar to 18 dollars. This reflects a slightly lower fair value despite improved expectations for revenue growth, profit margin, and a less demanding future price to earnings multiple.A Look At The Fair Value Of Core Laboratories Inc. (NYSE:CLB)
Nov 21Middle East And Asia Pacific Markets Will Secure Energy Success
With both the discount rate and future P/E ratio remaining essentially stable, the consensus analyst price target for Core Laboratories was unchanged at $14.00. What's in the News Core Laboratories issued third quarter 2025 guidance, expecting revenue of $127.5–134.5 million, operating income of $13.6–16.2 million, operating margin of approximately 11%, and EPS of $0.18–0.22.Core Laboratories Inc.'s (NYSE:CLB) 25% Jump Shows Its Popularity With Investors
Sep 10We Think Core Laboratories (NYSE:CLB) Is Taking Some Risk With Its Debt
Jul 24Core Laboratories (NYSE:CLB) Will Be Hoping To Turn Its Returns On Capital Around
Jul 03Is There An Opportunity With Core Laboratories Inc.'s (NYSE:CLB) 49% Undervaluation?
Jun 12Core Laboratories Inc.'s (NYSE:CLB) Price In Tune With Earnings
Apr 04Is Core Laboratories Inc. (NYSE:CLB) Trading At A 27% Discount?
Jan 21Core Laboratories Inc. (NYSE:CLB) Not Lagging Market On Growth Or Pricing
Jan 03Returns On Capital At Core Laboratories (NYSE:CLB) Paint A Concerning Picture
Dec 09Is Core Laboratories (NYSE:CLB) Using Too Much Debt?
Nov 12
New Product Launches And Deleveraging To Propel Growth Amidst Geopolitical Challenges
Diversification in geographical markets and services strengthens revenue by expanding market presence and targeting regions with growing demand.Is Core Laboratories Inc. (NYSE:CLB) Trading At A 38% Discount?
Sep 19What You Can Learn From Core Laboratories Inc.'s (NYSE:CLB) P/E
Aug 14We Think Core Laboratories (NYSE:CLB) Can Stay On Top Of Its Debt
Jul 15These Return Metrics Don't Make Core Laboratories (NYSE:CLB) Look Too Strong
Jun 25It's Unlikely That Core Laboratories Inc.'s (NYSE:CLB) CEO Will See A Huge Pay Rise This Year
May 02Is Core Laboratories Inc. (NYSE:CLB) Trading At A 25% Discount?
Mar 26Why We're Not Concerned About Core Laboratories Inc.'s (NYSE:CLB) Share Price
Mar 02Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($214.4M) de CLB superan a sus pasivos a corto plazo ($104.7M).
Pasivo a largo plazo: Los activos a corto plazo de CLB ($214.4M) superan a sus pasivos a largo plazo ($207.9M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: El ratio deuda neta-patrimonio (33.3%) de CLB se considera satisfactorio.
Reducción de la deuda: El ratio deuda-patrimonio de CLB ha pasado de 144.2% a 41.6% en los últimos 5 años.
Cobertura de la deuda: La deuda de CLB está bien cubierta por el flujo de caja operativo (30%).
Cobertura de intereses: Los pagos de intereses de la deuda de CLB están bien cubiertos por el BAIT (4.5x cobertura).
Hoja de balance
Descubre empresas con salud financiera
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/04 14:09 |
| Precio de las acciones al final del día | 2026/05/04 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Core Laboratories Inc. está cubierta por 30 analistas. 2 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| James West | Barclays |
| Nicholas Green | Bernstein |
| Saurabh Pant | BofA Global Research |